skip to content
Low Energy Hot Flashes Inflammation Cognition TRT Brain Fog

Survey: Millions of Americans Struggle to Access Hormone Care

A new Hone analysis reveals large swaths of the U.S. have little access to qualified hormone specialists.

woman in her 30s standing in the middle of a prairie looking off into the distance

At 28, Logan became what he calls a “walking zombie.” He had crushing fatigue, no sex drive, little emotion, and no motivation. Blood tests from his primary care doctor showed a testosterone level around 180 ng/dL, well below the standard diagnostic cutoff for low testosterone. But, because his doctor wasn’t experienced in prescribing hormone therapy — or the careful monitoring it requires — he referred Logan to an endocrinologist.

Logan, who lives in rural Michigan, waited three months for an appointment and drove 90 minutes to get there. After reviewing multiple blood tests over several months showing testosterone levels between 100 and 302 ng/dL, the endocrinologist told him his numbers were fine and his symptoms must have another cause. “I felt hopeless,” Logan says. “I knew what I was feeling, and no one was willing to help me.”

Logan lives in what longevity platform Hone Health calls a “hormone desert” — a geographic area where residents lack access to qualified hormone health providers. These hormone deserts are ubiquitous across the country, especially in the South, the Midwest, and in rural areas, according to a new analysis by Hone Health comparing U.S. census data with registries of menopause-certified physicians and board-certified urologists.

“Your ZIP code shouldn’t determine whether your hormones get treated, but for millions of Americans, that’s exactly what’s happening,” says Jim Staheli, D.O., Medical Director of Hone Health. “When people can’t access qualified hormone care, they don’t just live with symptoms longer — they miss opportunities for early diagnosis, losing the chance to reduce their risk of chronic diseases before they become much harder to treat.”


About the Experts

Joshua Calvert, M.D., is a urologist who specializes in male infertility and low testosterone management. 

Jim Staheli, D.O., is the Medical Director for Hone Health and a family medicine doctor who specializes in longevity and hormone optimization. 


Hormone Care Availability Across the U.S. 

Many less densely populated states such as Mississippi, Idaho, Oklahoma, Iowa, Wyoming, and Nevada have become hormone deserts, according to Hone Health’s analysis, but even more densely populated states may have regions where patients struggle to find qualified care.

Top hormone deserts for men

  • Nevada and Wyoming each have only 1 board-certified urologist per 10,000 men aged 40–64.
  • Arkansas, Georgia, Hawaii, Idaho, Iowa, Mississippi, Missouri, Nebraska, New Mexico, North Dakota, Oklahoma, Texas, and Utah have 2 urologists per 10,000 men.
  • California has 2.5 urologists per 10,000 men, but providers are concentrated in San Francisco, San Jose, and Los Angeles, while most of the San Joaquin Valley is a desert.


To understand the impact of these hormone deserts, consider Nevada as an example. With one urologist for every 10,000 men, and testosterone deficiency affecting an estimated 1 in 4 men ages 40–64, each urologist in Nevada would need to see 10 patients per day to meet annual demand.1 And that’s on top of all their patients with prostate cancer, kidney stones, bladder disorders, and other urological symptoms. 

lack of access to hormone care for men by us state map

Top hormone deserts for women

  • Mississippi has roughly 1 menopause-certified physician for every 79,000 women aged 40–64.
  • Alabama, Idaho, and Oklahoma each have roughly 1 menopause-certified physician for every 50,000 women in that age bracket. 
  • Alaska, Iowa, Nevada, South Carolina, and Tennessee each have roughly 1 menopause-certified physician for every 33,000 women in the target age range. 
  • Colorado, which has 1 provider for roughly every 12,000 women 40–64, lacks trained physicians in the highly rural northeast region of the state.


The landscape of specialized hormone care in the U.S. is even bleaker for women, leaving many without help around perimenopause and menopause, a time when symptoms can severely compromise quality of life and chronic diseases often begin to take hold. 

With one menopause-certified physician for every 79,000 women in Mississippi, for example, and an estimated 75% of women experiencing symptoms significant enough to affect quality of life, a single specialist would need to see 237 patients per day to meet annual demand — more than 10 times what a full clinical schedule allows.2

lack of access to hormone care for women by us state map

Where hormone providers are more abundant

Overall, OB/GYNs and urologists are most concentrated in parts of New England, the mid Atlantic, and major cities like Seattle, Olympia, Washington, San Francisco, San Jose, New Orleans, Minneapolis, Cleveland, Chicago, and Charlotte, Virginia. However, rural parts of those states and many Mountain States have virtually no providers. Some densely populated states, like New York and New Jersey, don’t make the list because even though there are many qualified providers, patients may still need to wait weeks or months for an appointment. 

Rural areas have fewer hormone providers 

Rural areas across the country have lower concentrations of medical providers generally.3 The American Urology Association reports that rural residents travel an average of 50 miles to see a urologist — more than five times farther than patients living in cities need to travel.4

This means residents of rural towns go months between the time they book an appointment and when they see their specialist. A 2022 study found they wait 10 weeks longer than urban patients for diagnostic and therapeutic procedures.5

Cities can have long wait times, too

Even in major cities, most men and women have to wait at least two weeks to see a hormone specialist. 

  • A two-week wait is the federal criterion for health deserts — an area, population group, or facility that the Secretary of Health and Human Services determines has a shortage of health professionals.6
  • Patients have to wait an average of 42 days to see an OB/GYN in a major metropolitan area, according to a survey by AMN Healthcare.7
  • And in a 2022 study, the average wait in the Chicago metropolitan area to see a urologist about blood in the urine (a serious symptom that could indicate a urinary tract infection, kidney stones, an enlarged prostate, kidney disease, or urinary tract cancers), was 15 days.8 9 

Not All Physicians are Trained in Hormone Care

These provider numbers and wait times don’t even take into account that not all OB/GYNs are knowledgeable about menopause, and not all urologists recommend TRT. That means even where there are accessible doctors, they may not be qualified to provide midlife hormone care.

Hone Health’s patient data validates what the provider maps suggest: When qualified local care isn’t available, people may look elsewhere. Many turn to telehealth. 

Men’s care

Nevada and Wyoming — the two worst urologist deserts in the country — rank first and second in Hone male patients, with more than double the national Hone average. Idaho, New Mexico, and Oklahoma, all bottom-tier for urologist access, also show well above-average Hone representation. The inverse is also true: States with the strongest urologist networks show the lowest Hone concentrations in states where Hone operates.

hone availability vs hormone deserts for men scatterplot

Women’s care

The women’s data tell the same story. Among women who seek hormone care through Hone Health, the highest per capita demand comes from the state of Nevada, where hormone specialists are scarce. Oklahoma and Tennessee — both severe hormone-specialist deserts — also rank above average in telehealth patients.

Why Hormone Deserts Exist

Hormone deserts exist for many of the same reasons other specialty care deserts do: Physicians want to live where reimbursement rates are higher and caseloads are more varied, leaving rural and low-income areas underserved. In hormone care specifically, this preference for denser, wealthier geographic areas is compounded by gaps in provider training, inconsistent prescribing guidelines, and narrow insurance coverage for hormone testing.

hormone treatment access unit chart for men and women in the us

Menopause care

Only 31% of OB/GYN residency programs in the U.S. include menopause training, and a quarter of those programs don’t have dedicated menopause clinics. That means residents don’t get hands-on experience with OB/GYN patients, leaving them feeling underprepared to treat this life stage.10 

Primary Care Providers (PCPs) are even less informed, with 20% of family medicine residents receiving zero menopause education, and less than 7% saying they feel qualified to help patients manage menopause.11

Testosterone care

PCPs are similarly ill-equipped to manage testosterone replacement therapy (TRT). Differing prescribing guidelines on testosterone therapy from the AUA, American College of Physicians, and other organizations causes confusion and may contribute to the fact that PCPs are less likely than urologists or endocrinologists to prescribe testosterone. 12 13

“Primary care doctors get maybe a few hours of training on testosterone therapy in their entire residency, and then we hand patients three different sets of guidelines that don’t agree with each other,” says urologist Joshua Calvert, M.D. “The safe move, from where they’re sitting, is to do nothing. I don’t blame them but it means the guy with textbook low-T symptoms sits in a waiting-room loop for months before he ever gets to someone who treats this every week.”

Compounding the problem is that insurance reimbursement for hormone testing is narrow: Most plans cover lab tests only when a patient has certain qualifying symptoms or is already on therapy. That policy creates a structural disincentive for comprehensive testing — even though optimal treatment requires a multi-hormone baseline established early and rechecked regularly.

The Compounding Cost of Hormone Deserts

When people can’t access hormone care from experienced providers, they often live with symptoms that seriously compromise their quality of life. Over time, they’re more likely to develop diagnoses that are harder to treat.

For women, menopause brings hot flashes, mood shifts, brain fog, and other symptoms, but it’s also a health inflection point, where decreasing estrogen levels begin to negatively impact cardiovascular health, bone density, and cognitive function. Long-term untreated menopause symptoms are linked to increased rates of chronic disease as well as reduced work productivity, relationship strain, depression, and anxiety.14 15

Men are often unaware that their fatigue, low libido, muscle loss, and weight gain can be hormonal. “Almost every week I have a man in his 40s tell me he thought his fatigue and brain fog were just ‘getting older,’” Calvert says. 

Waiting years to check a number that takes one blood draw comes at a real cost, Calvert notes. Without TRT, men with low testosterone are 86% more likely to develop depression, and more than twice as likely to develop metabolic syndrome, which is the on-ramp to diabetes and heart disease.16 17 On the flip side, men with testosterone levels above 450 ng/dL have a 42% lower risk of developing type 2 diabetes than men whose levels are lower.18

Even men who suspect their symptoms are due to a testosterone deficiency may be denied  hormone therapy if their levels are above the 300 ng/dL cutoff suggested in the guidelines from organizations like the Endocrine Society or the AUA. But doctors who specialize in health optimization note that men with testosterone levels slightly above this can be highly symptomatic and often benefit from TRT. That’s in part because you can have high total testosterone but low free testosterone, which is the type your body actually uses.

“Some testosterone is bound so tightly to proteins that your body can’t use it. What’s more important is how much testosterone is actually available to your tissues,” Calvert says. “I’ve seen men with a ‘normal’ total testosterone level around 400 who still had symptoms because their bioavailable testosterone was low. If you look only at the total number, it can seem like nothing’s wrong.”

Men with lower levels of testosterone may simply struggle with symptoms, or they may turn to unregulated testosterone clinics with minimal oversight, or online gray-market suppliers.19 20 Taking testosterone from unproven sources and without physician monitoring can be dangerous, leading to cardiovascular issues, infertility, and other side effects from improperly high testosterone.

Closing the Gap

Getting care to residents of hormone deserts requires action by medical schools, insurance companies, and telehealth providers, says Staheli:

  • Medical education reform: Integrating menopause and hormone health into residency training and continuing medical education requirements would help equip more providers, especially those in primary care, to diagnose and treat these concerns. Not having to refer patients to specialists would dramatically improve access to care.  
  • Credentialing expansion: Increasing awareness of the Menopause Society’s certification program, particularly among nurse practitioners and physician assistants, and encouraging urology practices to train mid-level providers in testosterone management would expand the pool of qualified hormone care providers.
  • Reimbursement reform: An initial hormone workup can take 20–45 minutes or longer, Staheli says, but primary care visits budget for only 10–18 minutes on average.21 Policy changes — such as adding hormone-related diagnoses to chronic care management billing codes and creating time-based billing pathways for the initial workup — would help make these time-intensive visits more financially viable for PCPs.
  • High-quality telehealth: Optimal hormone and midlife care requires comprehensive blood testing of related biomarkers, ongoing monitoring, and one-on-one video calls with physicians who are menopause-certified or up on the latest evidence for HRT, TRT, and other hormone protocols, such as thyroid therapies.

What people in hormone deserts can do right now

Ask your primary care physician for a referral or check the Menopause Society’s directory to find the nearest qualified menopause practitioner. (There’s no equivalent directory for urologists — the AUA recommends checking directories like Healthgrade.) You can also explore high-quality telehealth options from anywhere in the U.S.

“Patients shouldn’t mistake a lack of access for a lack of options,” Staheli says. “If qualified care isn’t available where you live, there are still ways to connect with experienced hormone specialists.”

After seeing a Facebook ad for Hone Health, Logan eventually started testosterone replacement therapy in 2024, at age 34. “Within three weeks, I noticed an energy that I had not felt in a long time,” he says. “It was a deep energy, like a fire in my soul that was rekindling. Around six months into therapy, I was literally a new person. I felt happiness, deep love, and an intense drive unlike I ever have in my life.” 

Data & Methodology

To qualify our definition of a hormone desert, we compared U.S. Census data of the population of women and men ages 40–64 in each state to the number of menopause-certified physicians (per the Menopause Society’s directory) and the number of board-certified urologists (per the American Urological Association’s 2025 Census) in each state, respectively. We then used the FutureDocs Forecasting Tool from the Cecil G. Sheps Center for Health Services Research to create maps of the number of OB/GYNs and urologists per 10,000 people (a standard baseline used by the World Health Organization to measure physician density)  in each geographic area served by a major medical center in 2025.

  1. Patel P, Fantus R, Lokeshwar S, et al. (2020) Trends in Serum Testosterone Levels Among Adolescent and Young Adults Men in the United States. Abstract MP78-01.

  2. Kapoor, Ekta, et al. (2025) Addressing Menopause Symptoms: Barriers and Opportunities for Improvement

  3. USDA (2023) Availability of healthcare providers in rural areas lags that of urban areas

  4. Sheyn, David. (2025) Rural Health Disparities in Urologic Care

  5. Garg, Tullika, et al. (2022) Demographic and Practice Trends of Rural Urologists in the U.S.: Implications for Workforce Policy

  6. Cornell Law School Legal Information Institute (1992) Criteria for Designation of Areas Having Shortages of Primary Medical Care Professional(s)

  7. AMN Healthcare. (2025) 2025 Survey of Physician Appointment Wait Times and Medicare and Medicaid Acceptance Rates

  8. National Institutes of Health (2025) Urine – Bloody

  9. Singh, Armaan, et al. (2022) Advanced Practice Providers and Wait Times in Urology Offices: A Secret Shopper Study

  10. Allen, Jennifer T, et al. (2023) Needs assessment of menopause education in United States obstetrics and gynecology residency training programs

  11. Kling, Juliana M, et al. (2019) Menopause Management Knowledge in Postgraduate Family Medicine, Internal Medicine, and Obstetrics and Gynecology Residents: A Cross-Sectional Survey

  12. Lawrence, Kristi L, et al. (2017) Approaches to male hypogonadism in primary care

  13. Jasuja, Guneet K, et al. (2017) Provider and Site-Level Determinants of Testosterone Prescribing in the Veterans Healthcare System

  14. Yildirim, Fatma, et al. (2023) The Effect of Menopause on the Sexual Functions and Marital Adjustment of the Spouses

  15. Kulkarni, Jayashri, et al. (2024) Menopause depression: Under recognised and poorly treated

  16. Ford, Andrew H, et al. (2016) Prospective longitudinal study of testosterone and incident depression in older men: The Health In Men Study

  17. Bhattacharya, Rajib K, et al. (2011) Effect of 12 months of testosterone replacement therapy on metabolic syndrome components in hypogonadal men: data from the Testim Registry in the US (TRiUS)

  18. Beatrice, Anne M, et al. (2014) Testosterone levels and type 2 diabetes in men: current knowledge and clinical implications

  19. Northwestern Feinberg School of Medicine (2023) Direct-to-Consumer Online Platforms Expand Access, but Often Fail to Convey Risks of Testosterone Therapy

  20. Aguiar JA, et al. (2026) Testosterone use trends among young men in the era of direct-to-consumer healthcare

  21. Neprash  HT, et al. (2021)  Measuring primary care exam length using electronic health record data

Editorial Policy: Science-Backed, Expert-Reviewed

The Edge upholds the highest standards of health journalism. We source research from peer-reviewed medical journals, top government agencies, leading academic institutions, and respected advocacy groups. We also go beyond the research, interviewing top experts in their fields to bring you the most informed insights. Every article is rigorously reviewed by medical experts to ensure accuracy. Contact us at support@honehealth.com if you see an error.

Share this article